1-3 of 3
O. Giles Best, BSc, PhD
Close
Sort by
Journal Articles

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

O. Giles Best, BSc, PhD, Kyle Crassini, William s Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA
Journal: Blood
Blood (2013) 122 (21): 4192.
https://doi.org/10.1182/blood.V122.21.4192.4192
Published: 2013
Journal Articles

The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MD, William E. P. Renwick, MBBS, FRACP, Melanie L Sulda, BSc, Ph.D, O. Giles Best, BSc, PhD, Bryone J Kuss, PhD, FRCPA, FRACP, MBBS, John F Seymour, MD, FRACP
Journal: Blood
Blood (2010) 116 (21): 699.
https://doi.org/10.1182/blood.V116.21.699.699
Published: 2010
Journal Articles

The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53

O. Giles Best, BSc, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA
Journal: Blood
Blood (2010) 116 (21): 2473.
https://doi.org/10.1182/blood.V116.21.2473.2473
Published: 2010